No Detail Found!

Effectiveness of combination therapy with sofosbuvir and daclatasvir in hcv infected patients

Author(s)
Zia Uddin Department of Medicine Lady Reading Hospital,Peshawar -,Pakistan
Shams Suleman Department of Pharmacology, Khyber Girls Medical College,Peshawar -,Pakistan
Shahzeb Department of Medicine, Mardan Medical Complex,Mardan -,Pakistan
Inayat Ullah Department of Medicine Lady Reading Hospital,Peshawar -,Pakistan
Shahab Uddin Zia Department of Medicine Lady Reading Hospital,Peshawar -,Pakistan
Zahid Fida Department of Medicine, Khyber Teaching Hospital,Peshawar -,Pakistan
Abstract
Objective: To determine the effectiveness of combination therapy with Sofosbuvir and Daclatasvir in HCV infected patients Material and Methods: This quasi experimental study spanning over six months from January 2019 till June 2019 was conducted in three tertiary care teaching hospitals of Khyber Pakhtunkhwa. A total of 255 RT-PCR confirmed genotype HCV infected patients were included. Combination therapy including standard dose Sofosbuvir (400mg) and Daclatasvir (60mg) regimen for 12 weeks was administered after recording baseline data. The SVR12 (sustained virologic response after 12 weeks) in these patients was observed by repeating the RT-PCR for HCV at 12 weeks after the completion of treatment. Results: This study included 108(42.35 %) male and 147 (57.64 %) female with male to female ratio of 1: 1.36 and Mean age 42.23 ± 11.9 years. Among them 200 (78.4%) were treatment naïve and 55 (21.6%) were treatment experienced. A total of 249 patients (97.6%) achieved SVR12 responders and 06 patients (2.4%) failed to achieve SVR12 non-responders. This response to DAA treatment for HCV was clinically and statistically significant. Conclusion: The standard three-month DAA therapy with Sofosbuvir and Daclatasvir for the treatment of HCV has better SVR12 when compared with conventional treatment.
Publication Details
Page(s) 239-243
DOI DOI not available
Published Journal: Journal of Medical Science, Volume: 28, Issue: 3, Year: 2020

Request the full text from PASTIC

Keywords
Sofosbuvir, Daclatasvir, Sustained Virologic Response (SVR12), Direct Acting Antiviral drugs (DAAs)
0

Citations

0

Downloads

59

Views